News | November 30, 2025
MHRA clears inavolisib, offering new option for returning breast cancer
The oral, film-coated tablet is licensed for patients whose cancer has returned during or shortly after hormone therapy
The oral, film-coated tablet is licensed for patients whose cancer has returned during or shortly after hormone therapy
The Complement Laboratory is equipped with state-of-the-art immunoturbidimetric and ELISA platforms and adheres to CAP and NABL accreditation standards
The Signia Circular Stapler is the only circular stapler on the market with integrated leak testing and features designed to minimize risk
Surgical site infections and antimicrobial resistance remain major challenges globally
Itvisma is a one-time, fixed-dose therapy designed to tackle the genetic root cause of SMA
Elevidys came under scrutiny in June when the FDA disclosed two fatal cases in non-ambulatory boys who developed dangerously high liver enzyme levels
These initiatives will harness top scientific talent and advanced AI technologies to develop new ways to slow the rise of drug-resistant infections
VLA1601 is a purified and inactivated vaccine specifically designed to protect against the Zika virus
Sotyktu continues to demonstrate consistent efficacy and safety across rheumatic conditions
Marks first international filing for Evofem’s single-dose oral treatment
Subscribe To Our Newsletter & Stay Updated
